2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Gene Editing, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Quality of Care, Diseases, Immunology, Autoimmune Disorders, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

1221 Pparβ/δ regulates antigen-driven CD4+ T cell activation and effector differentiation

Nicha Wareesawetsuwan, MD, Betul Ibis, MD2, Anthos Christofides, MD PhD3, Konstantinos Aliazis, PhD4, Rushil Shah, BSc5, Rinku Pal, BS6, Monisha Kashyap, MD7, Vassiliki Boussiotis, MD PhD8
1 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, University of Minnesota-Twin Cities, Minneapolis, Minnesota, United States
2 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, Mt. Auburn Hospital, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States, Ohio State University Medical College, Columbus, Ohio, United States
6 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
7 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
8 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States

Peroxisome proliferator-activated receptor β/δ (Pparβ/δ) is a fatty acid-activated nuclear transcription factor that regulates metabolic programs and has emerging roles in immune cell fate and function. Pparβ/δ is ubiquitously expressed and has been implicated in T cell development and function, although prior studies have reported divergent effects. While Pparβ/δ may support TCRβ-selected thymocyte proliferation and peripheral CD4+ T cell expansion, overexpression of Pparβ/δ can suppress DN4 thymocyte proliferation by shifting metabolism toward fatty acid oxidation. In autoimmune models, Pparβ/δ deficiency enhances Th1 and Th17 polarization while reducing Th2 and Treg differentiation, suggesting that Pparβ/δ regulates metabolism-dependent T cell differentiation fate. However, the T cell intrinsic role of Pparβ/δ in antigen (Ag)-driven and tumor-associated T cell responses remains poorly understood. In this study, we aimed to investigate how T cell-specific deletion of Pparβ/δ affects T cell composition, Ag-driven activation in vitro, and antitumor T cell responses in vivo. To achieve these goals, we crossed Pparβ/δfl/fl mice with CD4Cre mice, which express Cre under the control of the CD4 promoter and induce floxed gene deletion in all T cell subsets during thymic differentiation. Using this approach, we generated Pparβ/δfl/flCD4Cre mice with conditional Pparβ/δ deletion in T cells and compared the in vitro and in vivo functions of their T cells with those from Pparβ/δfl/fl control mice. At baseline, Pparβ/δfl/flCD4Cre mice showed reduced CD4+ and increased CD8+ T cell fractions in the spleen and lymph nodes. This skewing persisted after anti-CD3/CD28 stimulation in vitro suggesting that Pparβ/δ ablation predominantly compromised expansion of CD4+ T cells. To investigate Ag-specific CD4+ T cell activation, we generated Pparβ/δfl/flCD4Cre/OT-II mice expressing an OT-II transgenic T cell receptor, which is expressed in CD4+ T cells and recognizes the ovalbumin-derived peptide OVA323-339 presented by MHC class II. At baseline, Pparβ/δfl/flCD4Cre/OT-II mice showed reduced CD4+ T cell frequency, and increased CD8+ T cell and Foxp3+ Treg cell frequency in the spleen and lymph nodes. These changes were accompanied by reduced CD4+ and CD8+ effector memory T cells. After 72 hours of in vitro Ag-specific stimulation with OVA323-339 peptide or polyclonal stimulation with anti-CD3/CD28, the CD4/CD8 skewing persisted across conditions. Moreover, Pparβ/δ-deficient T cells showed greater impairment in OVA-driven responses than in anti-CD3/CD28 driven responses supporting a key role of Pparβ/δ during antigen-specific stimulation of CD4+ T cells. Consistent with this, following OVA stimulation, Pparβ/δ-deficient CD4+ T cells demonstrated attenuated induction of CD25, CD44, and CD69, together with impaired CD4+ effector cell differentiation confirming that Pparβ/δ deletion preferentially impairs Ag-specific CD4+ T cell activation. In line with these findings, thymidine incorporation at 72 hours in total splenocyte cultures was more prominently reduced after OVA-mediated stimulation than anti-CD3/CD28 mediated stimulation. To characterize the role of T cell-intrinsic Pparβ/δ in antitumor immunity in vivo, we compared Pparβ/δfl/flCD4Cre mice with Pparβ/δfl/fl controls in three different murine tumor models, the MC38 colon adenocarcinoma, MC17-51 fibrosarcoma, and B16-OVA melanoma. Pparβ/δ deletion significantly impaired tumor control in MC38 and MC17-51 tumors, as reflected by increased tumor volume and weight. A similar trend was observed in the B16-OVA tumor model, although the results did not reach statistical significance. Collectively, these results support a role for T cell-intrinsic Pparβ/δ in antitumor immunity, with its impact being more evident in the CD4+ T cell compartment. In conclusion, Pparβ/δ is an important regulator of Ag-driven CD4+ T cell activation, expansion, and effector differentiation. These findings suggest that therapeutic modulation of Pparβ/δ may be clinically relevant for optimizing antitumor T cell immunity.

Nicha Wareesawetsuwan, MD: No relevant conflicts of interest to declare.